Sugi Predict

Sugi Predict / Compounds / SCHEMBL423400

SCHEMBL423400

SCHEMBL423400

CN1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.65
▸ SMN1; SMN2 Q16637 3/20 0.65
▸ LMNA P02545 2/20 0.65
▸ ALOX12 P18054 2/20 0.65
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ ADRB1 P08588 1/20 0.61
▸ ALDH1A1 P00352 2/20 0.60
▸ BCL2 P10415 1/20 0.60
▸ BID P55957 1/20 0.60
▸ RAD51 Q06609 1/20 0.60
▸ BCL2L1 Q07817 1/20 0.60
▸ BCL2A1 Q16548 1/20 0.60
▸ BCL2L2 Q92843 1/20 0.60
▸ HTT P42858 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ HTR3A P46098 1/20 0.55
▸ MAPK1 P28482 2/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ GAA P10253 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8318825 0.86 MAPT (0.59) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL14922269 0.85 KMT2A (0.53) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL1779650 0.84 ADRB1 (0.53) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL3587877 0.83 HTR3A (0.50) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL22578903 0.83 MAPT (0.62) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL24309951 0.83 SIRT6 (0.56) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL20236384 0.83 MAPT (0.55) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL520755 0.83 MAPT (0.67) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL20308977 0.83 HSP90AA1 (0.56) MAPTSMN1; SMN2LMNAALOX12L3MBTL1
SCHEMBL29567153 0.83 SIRT6 (0.56) MAPTSMN1; SMN2LMNAALOX12L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170334-B1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION UNIV EMORY (US) 2021-03-17 — — EP disclosed
US-10000450-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 — — US disclosed
US-10000450-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 — — US disclosed
US-20170166524-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-06-15 — — US disclosed
US-20170166524-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-06-15 — — US disclosed
EP-1781661-B1 VASOPRESSIN V1A ANTAGONISTS VANTIA LTD (GB) 2017-06-07 — — EP disclosed
US-9611214-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-04 — — US disclosed
US-9611214-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-04 — — US disclosed
US-8906913-B2 Azabicyclohexanes PANACEA BIOTEC LIMITED (IN) 2014-12-09 — — US disclosed
US-20140288065-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-09-25 — — US disclosed
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-09-02 — — US disclosed
WO-2010062848-A1 SUBSTITUTED PYRAZOLE COMPOUNDS MIKANA THERAPEUTICS, INC. (US) 2010-06-03 — — WO disclosed
WO-2009053373-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-30 — — WO disclosed
US-20090088406-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-04-02 — — US disclosed
US-20090088406-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-04-02 — — US disclosed
US-20090029965-A1 Vasopressin V1a Antagonists FERRING B.V. (NL) 2009-01-29 — — US disclosed
US-20090029965-A1 Vasopressin V1a Antagonists FERRING B.V. (NL) 2009-01-29 — — US disclosed
EP-1757591-A1 CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-02-28 — — EP disclosed
WO-2006021213-A2 VASOPRESSIN V1A ANTAGONISTS FERRING B.V. (NL) 2006-03-02 — — WO disclosed
US-5945421-A TREATING PSYCHOSIS AND SCHIZOPHRENIA WARNER-LAMBERT COMPANY (US) 1999-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088406-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 MAPT 1263/4885SMN1; SMN2 1192/4885LMNA 3720/4885
US-10000450-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors SLC6A2, TPH1, SLC6A3 MAPT 1263/4885SMN1; SMN2 1192/4885LMNA 3720/4885
US-20170166524-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 MAPT 1263/4885SMN1; SMN2 1192/4885LMNA 3720/4885
US-20090029965-A1 Vasopressin V1a Antagonists AVPR1A, AVPR2, AVPR1B MAPT 4727/4885SMN1; SMN2 4623/4885LMNA 2881/4885
US-20100222348-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS PARP1, PARP2, PARP11 MAPT 2742/4885SMN1; SMN2 2658/4885LMNA 305/4885
US-20140288065-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 MAPT 1263/4885SMN1; SMN2 1192/4885LMNA 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.